Welcome to our dedicated page for AdvisorShares Psychedelics ETF news (Ticker: PSIL), a resource for investors and traders seeking the latest updates and insights on AdvisorShares Psychedelics ETF stock.
AdvisorShares Psychedelics ETF (PSIL) provides investors with focused exposure to companies advancing psychedelic-assisted therapies and biotechnology research. This news hub aggregates all official communications and market developments related to the actively managed ETF.
Access timely updates on portfolio adjustments, regulatory milestones, and sector analysis curated for investors monitoring this emerging healthcare niche. Our repository includes earnings commentary, management insights, and strategic filings – all essential for understanding PSIL's position in volatile biopharma markets.
Key coverage areas include clinical trial progress from underlying holdings, DEA scheduling updates impacting sector valuations, and the fund's active rebalancing strategies. Bookmark this page for consolidated access to PSIL's corporate actions and market disclosures, maintained with neutral reporting standards required for financial decision-making.
AdvisorShares has announced a 1-for-10 reverse split of the AdvisorShares Psychedelics ETF (PSIL), effective September 10, 2024. This will result in an approximate 90% decrease in outstanding shares. The split will not change the total value of shareholders' investments, but will increase the per-share NAV and market price by about ten times. The Fund's CUSIP will change from 00768Y362 to 00768Y297. Fractional shares will be redeemed for cash at the split-adjusted NAV. The reverse split may result in capital gains or losses for shareholders. AdvisorShares will provide a one-time opportunity for an authorized participant to redeem any resulting odd lot unit.
FAQ
What is the current stock price of AdvisorShares Psychedelics ETF (PSIL)?
